Denali Therapeutics Inc. Stock News

Over the past 3 months, 4 analysts have published their opinion on Denali Therapeutics (NASDAQ:DNLI) stock. These analysts are typically employed by large Wall Street banks and tasked with understandi

Denali Therapeutics Inc. has major partnerships and an active set of programs. They are flush with cash.

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to c

Upgrades According to JP Morgan, the prior rating for Callon Petroleum Co (NYSE:CPE) was changed from Underweight to Neutral. Callon Petroleum earned $4.04 in the third quarter, compared to $2.93 in t

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to c

Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -1.20% and 64.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the

The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.

The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.

Upgrades According to Evercore ISI Group, the prior rating for BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) was changed from In-Line to Outperform. In the third quarter, BioCryst Pharmaceuticals showed

Denali Therapeutics initiated a phase 3 study, using BIIB122 for the treatment of Parkinson's Disease patients with the pathogenic mutation of LRRK2, in October of 2022. The company initiated a phase

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 11,933,962 shares of

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its com

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $250 million of shares of its common stock in

Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.